Aristo Bio-Tech and Lifescience (NSE:ARISTO) Long-Term Debt: ₹76 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ARISTO Aristo Bio-Tech and Lifescience Ltd NSE:ARISTO
59 GF Score
Price ₹109.30
View Full Analysis

What is Aristo Bio-Tech and Lifescience Long-Term Debt?

Aristo Bio-Tech and Lifescience NSE:ARISTO 59 Long-Term Debt is ₹76 Mil as of Mar. 2025. GuruFocus rates NSE:ARISTO with a GF Score™ of 59/100.

Aristo Bio-Tech and Lifescience's Long-Term Debt for the quarter that ended in Mar. 2025 was ₹76 Mil.

Aristo Bio-Tech and Lifescience's quarterly Long-Term Debt declined from Mar. 2024 (₹100 Mil) to Sep. 2024 (₹85 Mil) and declined from Sep. 2024 (₹85 Mil) to Mar. 2025 (₹76 Mil).

Aristo Bio-Tech and Lifescience's annual Long-Term Debt declined from Mar. 2023 (₹102 Mil) to Mar. 2024 (₹100 Mil) and declined from Mar. 2024 (₹100 Mil) to Mar. 2025 (₹76 Mil).

Aristo Bio-Tech and Lifescience  (NSE:ARISTO) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Aristo Bio-Tech and Lifescience Long-Term Debt Related Terms

Aristo Bio-Tech and Lifescience Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Aristo Bio-Tech and Lifescience's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aristo Bio-Tech and Lifescience Long-Term Debt Chart

Aristo Bio-Tech and Lifescience Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Long-Term Debt
Get a 7-Day Free Trial 120.60 110.91 101.66 99.96 76.40

Aristo Bio-Tech and Lifescience Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only 101.66 95.25 99.96 84.78 76.40
NSE:ARISTO
59GF Score
Aristo Bio-Tech and Lifescience Ltd NSE:ARISTO
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹76 Mil mean?
Aristo Bio-Tech and Lifescience (NSE:ARISTO) has a Long-Term Debt of ₹76 Mil as of Mar. 2025.
Is Aristo Bio-Tech and Lifescience's Long-Term Debt too high?
Aristo Bio-Tech and Lifescience's current Long-Term Debt is ₹76 Mil. Overall, Aristo Bio-Tech and Lifescience has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Aristo Bio-Tech and Lifescience's Long-Term Debt compare to CTVA and CF?
Aristo Bio-Tech and Lifescience's Long-Term Debt of ₹76 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for an Agriculture company?
A good Long-Term Debt depends on the Agriculture industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Aristo Bio-Tech and Lifescience's current Long-Term Debt is ₹76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aristo Bio-Tech and Lifescience stock overvalued right now?
Aristo Bio-Tech and Lifescience (NSE:ARISTO) has a current Long-Term Debt of ₹76 Mil. The current Long-Term Debt is ₹76 Mil. Aristo Bio-Tech and Lifescience's overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Aristo Bio-Tech and Lifescience (NSE:ARISTO), the current Long-Term Debt is ₹76 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aristo Bio-Tech and Lifescience Business Description

Address E-24, 25, 26, G.I.D.C, Manjusar, Taluka Savli, Vadodara, GJ, IND, 391775
Aristo Bio-Tech and Lifescience Ltd is an agrochemical company. It is mainly engaged in the manufacturing, formulation, supplying, packaging and job work services of various pesticides. The company exports products like Insecticides, Herbicides, Fungicides, Plant Growth Regulators and a wide variety of other Agrochemicals.
59GF Score

Get the complete analysis for NSE:ARISTO

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹109.30
Price